Abstract | UNLABELLED: MATERIALS AND METHODS: Between October 1999 and September 2003, 5 patients were enrolled. The initial regimens were prescribed as adjuvant therapy in conjunction with radiotherapy following standard surgical treatment. All patients received a chemotherapy comprising ranimustine (100 mg/m2) intravenously on Day 1, procarbazine (60 mg/m2) on Days 8 to 21, and vincristine (1.4 mg/m2, maximum total 2 mg) on Days 8 and 29. The cycles were repeated every 8 weeks until tumor progression was evident, or for a total of 6 cycles over a 1-year period. The primary end-points were safety and tolerability, while the secondary end-point was overall survival. RESULTS: Five consecutive eligible patients were treated. Of the 4 evaluable patients, 3 partially responded to the treatment (PR), while 1 had a complete response (CR): all patients are still alive. However, 3 of the 5 patients showed relapse, with a time to tumor progression ( TTP) of 50, 143 and 241 weeks, respectively. Two of these patients received combined treatment with carboplatin, etoposide and recombinant human mutant tumor necrosis factor-alpha at the first relapse. This regimen appeared to be safe and neither neurological toxicity, severe or life-threatening hematological toxicity, nor fatal toxicity (WHO Grade 4) were experienced. CONCLUSION: These results suggest that a chemotherapy regimen consisting of PCB, MCNU and VCR in this patient population seems to be safe and tolerable, and the response rate was high. Thus, wide resection with a risk of major neurological morbidity due to nearby functionally critical areas can be avoided. However, since the relapse rate was high, a second-line chemotherapy should be developed for anaplastic oligodendroglioma to improve the long-term control of the disease.
|
Authors | Masaaki Yamamoto, Mitsutoshi Iwaasa, Masani Nonaka, Hitoshi Tsugu, Kazuki Nabeshima, Takeo Fukushima |
Journal | Anticancer research
(Anticancer Res)
2005 Nov-Dec
Vol. 25
Issue 6A
Pg. 3715-23
ISSN: 0250-7005 [Print] Greece |
PMID | 16302731
(Publication Type: Clinical Trial, Journal Article)
|
Chemical References |
- Nitrosourea Compounds
- Procarbazine
- Vincristine
- ranimustine
|
Topics |
- Adult
- Antineoplastic Combined Chemotherapy Protocols
(adverse effects, therapeutic use)
- Brain Neoplasms
(drug therapy, radiotherapy, surgery)
- Combined Modality Therapy
- Female
- Humans
- Male
- Middle Aged
- Nitrosourea Compounds
(administration & dosage, adverse effects)
- Oligodendroglioma
(drug therapy, radiotherapy, surgery)
- Procarbazine
(administration & dosage, adverse effects)
- Treatment Outcome
- Vincristine
(administration & dosage, adverse effects)
|